- Conditions
- Healthy Volunteers
- Interventions
- TAK-385 T2 Formulation, TAK-385 T4 Formulation B, TAK-385 T4 Formulation C
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 321
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- Nivolumab and rHuPH20, Nivolumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Buffalo, New York • West Reading, Pennsylvania
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance, BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
- Drug
- Lead sponsor
- Bexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Healthy
- Interventions
- ABT-450, ritonavir
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Waukegan, Illinois
- Conditions
- Healthy Participants
- Interventions
- Crizotinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Hepatitis C, HIV Infections
- Interventions
- Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Richmond, Virginia
- Conditions
- Healthy Volunteers
- Interventions
- Viagra 50 mg tablet, Formulation B ODT tablet 50 mg, Formulation C ODT tablet 50 mg, Formulation D ODT tablet 50 mg
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy, Seizures
- Interventions
- Ethosuximide, Lamotrigine, Valproic acid
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 30 Months to 13 Years
- Enrollment
- 453 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2016
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 28 more
- Conditions
- Pain
- Interventions
- Oxycodone
- Drug
- Lead sponsor
- Pain Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
- Interventions
- Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment
- Drug · Biological · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 640
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 456 more
- Conditions
- Chronic Spinal Cord Injury
- Interventions
- NVG-291, Placebo
- Drug
- Lead sponsor
- NervGen Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Pheonix, Arizona • Downey, California + 18 more
- Conditions
- Healthy
- Interventions
- Calderasib, PPI
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Rheumatoid Arthritis, Healthy Volunteers
- Interventions
- CE 224,535
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- SARS-CoV-2, Influenza, RSV
- Interventions
- mRNA-1010, mRNA-1345, mRNA-1273.214, mRNA-1045, mRNA-1230
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 392 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 14
- States / cities
- DeLand, Florida • Hollywood, Florida • St. Petersburg, Florida + 11 more
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- Carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, trastuzumab, magnetic resonance imaging, therapeutic conventional surgery
- Drug · Procedure
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 21 Years to 90 Years · Female only
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2021
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Healthy
- Interventions
- Palbociclib Formulation Reference, Palbociclib Formulation Test
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy
- Interventions
- AZD9742, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 23 Years to 45 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthy Subjects
- Interventions
- CC-90001
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Fair Lawn, New Jersey
- Conditions
- Infections, Meningococcal
- Interventions
- MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine
- Combination Product · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 10 Years to 50 Years
- Enrollment
- 1,440 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 12
- States / cities
- Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more
- Conditions
- Healthy Participants
- Interventions
- Nintedanib, BMS 986278
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Healthy
- Interventions
- ALXN1840, Omeprazole
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
- Interventions
- Rilonacept, Placebo
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Interventions
- paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, radiation therapy, paclitaxel, fluorouracil, hydroxyurea, cisplatin, laboratory biomarker analysis, quality-of-life assessment
- Drug · Radiation · Other + 1 more
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
- Interventions
- Nivolumab, Nivolumab + Relatlimab, Ipilimumab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida